The tumor suppressor Fhit and its substrate diadenosine triphosphate (Ap 3 A) are important factors in cancer development and progression. Fhit has Ap 3 A hydrolase activity and cleaves Ap 3 A into adenosine monophosphate (AMP) and adenosine diphosphate (ADP); this is believed to terminate Fhit-mediated signaling. How the catalytic activity of Fhit is regulated and how the Fhit·Ap 3 A complex might exert its growth-suppressive function remain to be discovered. Small-molecule inhibitors of the enzymatic activity of Fhit would provide valuable tools for the elucidation of its tumor-suppressive functions. Here we describe the development of a high-throughput screen for the identification of such small-molecule inhibitors of Fhit. Two clusters of inhibitors that decreased the activity of Fhit by at least 90 % were identified. Several derivatives were synthesized and exhibited in vitro IC 50 values in the nanomolar range.
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The fragile histidine triad protein (Fhit) is a tumor suppressor, and the associated gene is often mutated in lung, [1] kidney, [2] esophagus, [3] breast, [4] and many other types of human cancer. [5] The gene is located on chromosome 3p14.2, which spans one of the most fragile sites of the genome: FRA3B. [3] Upon complex formation with two molecules of diadenosine triphosphate (Ap 3 A), the tumor-suppressive function of Fhit and hence the signaling pathway towards apoptosis are believed to be activated. [5, 6] Additionally, Fhit also displays Ap 3 Aase activity and cleaves Ap 3 A into adenosine monophosphate (AMP) and adenosine diphosphate (ADP). This is believed to terminate Fhit-induced signaling [7] because it was previously reported that Fhit mutants without hydrolase activity still show tumor-suppressive function, whereas Ap 3 A-binding mutants are inactive in this respect. [6, 8] Furthermore, reinstatement of the FHIT gene in Fhit-negative tumor cells resulted in significant inhibition of cell proliferation and increased apoptosis in vitro [9] [10] [11] and in decreased tumorigenicity in vivo. [6] Because the lifetime of the Fhit·Ap 3 A complex is believed to determine the level of tumor suppression it is suggested that stress conditions in vivo result in reduced Ap 3 Aase activity. [12] On investigation of this hypothesis, it was discovered that Fhit might be regulated by Src-kinase-mediated phosphorylation. [12, 13] The importance of Fhit and its enzymatic activity for cellular function was further demonstrated by the observation that a nonhydrolyzable Ap n A analogue triggers Fhit-dependent and caspase-directed apoptosis. [14] The exact mechanisms of how Fhit activity and the Fhit· Ap 3 A-mediated signaling pathway act and are regulated, however, still remain to be discovered. Small-molecule inhibitors of the enzymatic activity of Fhit would provide tools that could assist in the elucidation of its functions in this context. Only a few molecules that are able to inhibit Fhit's enzymatic activity have been reported to date. Among these, suramin [15] and noncleavable Ap n A analogues, [16] [17] [18] as well as transition metal ions such as Cu 2 + and Zn 2 + , [19] have been presented over the years. Cu 2 + and Zn 2 + , however, inhibit Fhit rather unspecifically because they have many other functions and targets within cells. Suramin also inhibits several different classes of enzymes. [20, 21] Reported IC 50 values of ZnCl 2 and suramin towards Fhit are in the micromolar rather than the nanomolar range. [22] Overall, small-molecule inhibitors of Fhit would be of considerable interest but had not been described previously.
In the hope of discovering potent small-molecule inhibitors of Fhit, we set out to develop a high-throughput screening assay to identify inhibitors of the enzymatic activity of Fhit from small-molecule compound libraries. Recently we reported the synthesis and application of 1 (Figure 1 A) , a doubly labeled Ap 3 A probe capable of undergoing FRET, the fluorescence characteristics of which change drastically upon enzymatic cleavage by Fhit. [22] The cleavage of the FRET pair SulfoCy3/Sulfo-Cy5 can readily be followed by measuring the fluorescence intensity at 590 nm, the maximum emission of the donor Sulfo-Cy3. Therefore, this approach is ideally suited as a high-throughput format for the identification of effectors of Fhit's enzymatic activity.
Using the assay shown in Figure 1 B, we screened 15 136 compounds from libraries from ChemBioNet, ChemDiv, and Maybridge, available in the screening facility at the University of Konstanz, for inhibition of Fhit's enzymatic activity. For this purpose, Fhit (6 nm) and screening buffer were placed in 384-well plates and incubated with the appropriate compounds (10 mm) at 258C for 30 min. FRET probe 1 (500 nm) was added, and fluorescence intensity with l em = 590 nm (l ex = 535 nm) was measured after t 0 = 0 min and t 1 = 30 min. The difference in fluorescence intensity relative to a DMSO control containing none of the small-molecule compound was calculated. In total, we found 45 compounds that inhibited the enzymatic activity of Fhit by at least 90 % (Figures S1 and S2 in the Supporting Information). The statistical parameters of the high-throughput screening were excellent, with an average z-score over all plates of 0.860 AE 0.032 and a strictly standardized mean difference (SSMD) value of À27.244 AE 6.572.
The best initial hit from the screening was compound 2 (Figure 2 A) , which reduced Fhit activity to less than 2 % of that of the DMSO control. To validate this result, compound 2 was synthesized according to a previously reported microwave-assisted procedure from dimedone, 3-amino-5-methylpyrazole, and 4-chlorobenzaldehyde. [23] Compound 2 was then employed at different concentrations in an in vitro dose/response FRET assay, similar to the screening procedure but with measurements taken every 3 min over 60 min (Figure 2 B) . Corresponding to the linear time response of the cleavage of 1, a concentration of 1 nm of Fhit was applied in the dose/response assay ( Figure S3 ). In this way, the IC 50 value of 2 was determined to be (199 AE 10) nm (Figure 2 C) .
Overall we identified one main structural motif-7,7-dimethyl-4,6,7,8-tetrahydro-1H-quinolin-5-one (Scheme 1)-in the screening; it was found in several derivatives among the best 45 hits. Besides the best inhibitor of the screening, compound 2, with a methylpyrazolo group bridging positions R 1 and R 2 , we also discovered inhibitors possessing an indeno motif substituted at R 1 and R 2 (Scheme 1 B). The screening results further indicated that bulky groups at R 3 significantly compromise activity, thus indicating that this part of the molecule should be tightly bound to the protein. We therefore chose to improve the inhibitory properties of these initial scaffolds by synthesizing derivatives differing in position R 3 . Hence, we set out to synthesize derivatives (Scheme 1 B) based either on the methylpyrazolo motif (cluster I, 2-10) or on the indeno motif (cluster II, 11-19). Lead compound 2 was the only one containing a methylpyrazolo group at R 1 and R 2 in the screening. In the case of the cluster II compounds, ptolyl-(compound 11), 4-ethylphenyl-(compound 12), and thiophen-2-yl-substituted (compound 19) derivatives had already been identified in the screening and inhibited Fhit activity by more than 95 % at 10 mm.
The synthesis of the compounds of both clusters was carried out in a one-pot manner with microwave-assisted heating (Schemes 1 C and D). In the case of cluster I, the commercially available starting materials dimedone, 3-amino-5-methylpyrazole, and the appropriate aldehydes were mixed in a 1:1:1 ratio and heated to 170 8C in aqueous medium with 1.2 equiv. of NEt 3 in a microwave for 15 min. Precipitation with EtOH/H 2 O (1:1) and subsequent filtration yielded the products. The synthesis of compounds 2-10 has been reported previously, except for that of compound 4, which was synthesized in analogy to the literature. [23, 24] Derivatives of cluster II were synthesized from indane-1,3-dione, 3-amino-5,5-dimethylcyclohex-2-enone, and the appropriate aldehydes in a 1:1:1 ratio. p-TsOH was added, and the mixtures were heated in a microwave at 150 8C in H 2 O for 10 min. The reactions were quenched with 10 % NaOH, and the compounds were purified by silica gel column chromatography and reversed-phase medium-pressure column chromatography. The synthesis of compounds 14 and 15 has been described previously. [25, 26] To the best of our knowledge, the other cluster II compounds had not been synthesized before. In total, 18 compounds were synthesized. The yields are given in Scheme 1 E.
Next, we tested the inhibitory potential of the synthesized compounds by use of the in vitro FRET assay described above. Four compounds-12, 13, 14, and 15-were found to inhibit Fhit more potently than lead compound 2. Interestingly, all of these compounds are from cluster II, and all the derivatives based on this structural motif are better inhibitors than the corresponding cluster I derivatives with the same R 3 group. The halogenated and alkylated structures have higher inhibitory potentials than the pyridinyl-and the thiophen-2-yl-substituted derivatives. The Br-substituted compound 15 is the most potent inhibitor, with an IC 50 value of (49 AE 7) nm, followed by its Cl-[compound 14, (51 AE 32) nm], Et-[compound 12, (125 AE 44) nm], and F-substituted [compound 13, (154 AE 55) nm] counterparts. The effect of the halogenated and alkylated compounds might be due to the altered electronic properties of the aromatic systems. The IC 50 values of all synthesized compounds are shown in Table 1 (the associated dose/response curves are displayed in Figure S4 ).
Because the synthesized compounds are conjugated p-systems, an additional negative control was performed, studying the influence of the potential inhibitors on the FRET assay being studied when no Fhit was applied. We found that all inhibitors had no effect on the fluorescent read-out ( Figure S5) . Furthermore, as shown by the results of the structure-activity relationship, slight changes in compound structure that do not alter the p-system can alter the inhibitory potential significantly (e.g., see IC 50 values of compounds 2 and 9). Furthermore, several other compounds with conjugated p-systems were screened and did not show any inhibition of Fhit ( Figure S6 ). This shows that the depicted system is highly sensitive to slight structural changes in the small-molecule system, excluding the possibility that just any extended aromatic system is an inhibitor.
Compound 15 was further tested on its effect on Fhit when the natural substrate Ap 3 A was used instead of probe 1. As analyzed by HPLC, Fhit was competitively inhibited by 15 when the Fhit/inhibitor ratio was 1:1000 and higher, a value that corresponds well with that determined in the FRET assay (Figure S7 A) .
To examine details about the enzymatic inhibition of Fhit further, another FRET-based assay was conducted. Here increasing amounts of substrate 1 were applied to preincubated mixtures of inhibitor 15 and Fhit. A higher turnover was achieved with rising concentrations of 1 (Figure S7 B) . This sug- gests that 15 does not covalently modify enzyme residues that are crucial for catalysis.
Next, all compounds were tested for their cytotoxic properties in the HEK 293T and lung cancer H1299 cell lines that are often used in Fhit research. [14, [27] [28] [29] A colorimetric assay that determines the metabolic activity of cells, and thus cell viability, as a function of the reduction of the tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) into insoluble formazan by NAD(P)H-dependent oxidoreductases was employed. [30] The results for the halogenated cluster II compounds 13, 14, and 15 are displayed in Figure 3 A and B (the MTT results for all compounds are displayed in Figure S8 ). All three compounds show similar cytotoxicity. Interestingly, HEK 293T cells are more sensitive to the Fhit inhibitors than H1299 cells. The viability of the former is already affected in the 10 mm range, whereas the latter still exhibit more than 50 % viability even when 100 mm of compound are applied. Overall, the compounds show moderate to no cytotoxicity, depending on the cell line, and are therefore ideally suited for further in vivo studies.
In conclusion, we have developed a high-throughput assay using FRET-Ap 3 A probe 1 to identify a main structural motif as a potential small-molecule inhibitor of the activity of the tumor suppressor Fhit. On this basis, we synthesized 18 compounds, the synthesis of several of them not previously reported, and identified five of these-2, 12, 13, 14, and 15-that inhibited Fhit with IC 50 values of < 200 nm. The best inhibitor, compound 15, had an IC 50 value of (49 AE 7) nm and was bound by Fhit in a reversible manner.
The compounds were further tested for their cytotoxic properties towards HEK 293T and H1299 cells, two cell lines commonly studied in Fhit research. The inhibitors showed moderate to no cytotoxicity, with HEK 293T cells seeming to be more affected than H1299 cells. Interestingly, HEK 293T cells constitutively express Fhit, [27] whereas H1299 are Fhit-negative. [31] Overall we identified several highly effective Fhit inhibitors that should be useful for study of the enzymatic activity of Fhit in more detail under various conditions. However, in human cells seven members of the histidine triad (HIT) protein family, including Fhit, have been described. [32, 33] Because the applied high-throughput screening was not designed to discriminate between the members, inhibition of other HIT family proteins cannot be excluded. Nevertheless, the discovered molecular scaffolds could eventually contribute to the development of new compounds for use in anticancer therapies to trigger Fhitdependent apoptosis.
